Multivariate analysis testing TMTV, with interim PET response after 2 cycles (iPET2) and individual baseline factors, EORTC, GHSG, NCCN staging systems
| TMTV tested with . | PFS* . | PFS (final model) . | OS* . | OS (final model) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Individual factors | ||||||||||||
| TMTV >147 cm3 | 3.9 | 1.6-9.5 | .0032 | 4.4 | 2.0-9.5 | .0002 | 3.7 | 0.9-14.6 | .066 | 5.5 | 1.7-17.9 | .0043 |
| IPET 2 | 11.0 | 4.8-25.1 | <.0001 | 10.9 | 4.9-24.4 | <.0001 | 11.3 | 3.2-39.9 | .0002 | 11.1 | 3.4-36.4 | <.0001 |
| B symptoms | 2.1 | 0.9-4.8 | .076 | 2.6 | 0.7-9.5 | .16 | ||||||
| ≥4 involved sites | 2.0 | 0.8-5.2 | .16 | 3.4 | 0.9-12.3 | .065 | ||||||
| M/T ≥ 0.35 | 0.8 | 0.3-2.0 | .65 | 0.6 | 0.2-2.4 | .51 | ||||||
| EORTC | ||||||||||||
| TMTV >147 cm3 | 3.5 | 1.6-7.8 | .0016 | 4.4 | 2.0-9.5 | .0002 | 3.9 | 1.2-12.4 | .024 | 5.5 | 1.7-17.9 | .0043 |
| IPET2 | 9.2 | 4.1-20.6 | <.0001 | 10.9 | 4.9-24.4 | <.0001 | 8.8 | 2.7-28.7 | .0003 | 11.1 | 3.4-36.4 | <.0001 |
| U EORTC | 3.2 | 0.9-11.1 | .067 | — | — | .9 | ||||||
| GHSG | ||||||||||||
| TMTV >147 cm3 | 4.1 | 1.8-9.3 | .0006 | 4.4 | 2.0-9.5 | .0002 | 4.8 | 1.4-16.3 | .0115 | 5.5 | 1.7-17.9 | .0043 |
| IPET2 | 10.6 | 4.7-23.9 | <.0001 | 10.9 | 4.9-24.4 | <.0001 | 10.4 | 3.1-34.2 | .0001 | 11.1 | 3.4-36.4 | <.0001 |
| U GHSG | 1.3 | 0.4-4.0 | .69 | 2.0 | 0.2-17.2 | .55 | ||||||
| NCCN | ||||||||||||
| TMTV >147 cm3 | 3.7 | 1.7-8.4 | .00014 | 4.4 | 2.0-9.5 | .0002 | 4.3 | 1.3-14.6 | .0182 | 5.5 | 1.7-17.9 | .0043 |
| IPET2 | 10.2 | 4.5-22.8 | <.0001 | 10.9 | 4.9-24.4 | <.0001 | 10.2 | 3.1-33.4 | .0001 | 11.1 | 3.4-36.4 | <.0001 |
| U NCCN | 1.8 | 0.6-5.7 | .30 | 2.9 | 0.3-25.0 | .34 | ||||||
| TMTV tested with . | PFS* . | PFS (final model) . | OS* . | OS (final model) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Individual factors | ||||||||||||
| TMTV >147 cm3 | 3.9 | 1.6-9.5 | .0032 | 4.4 | 2.0-9.5 | .0002 | 3.7 | 0.9-14.6 | .066 | 5.5 | 1.7-17.9 | .0043 |
| IPET 2 | 11.0 | 4.8-25.1 | <.0001 | 10.9 | 4.9-24.4 | <.0001 | 11.3 | 3.2-39.9 | .0002 | 11.1 | 3.4-36.4 | <.0001 |
| B symptoms | 2.1 | 0.9-4.8 | .076 | 2.6 | 0.7-9.5 | .16 | ||||||
| ≥4 involved sites | 2.0 | 0.8-5.2 | .16 | 3.4 | 0.9-12.3 | .065 | ||||||
| M/T ≥ 0.35 | 0.8 | 0.3-2.0 | .65 | 0.6 | 0.2-2.4 | .51 | ||||||
| EORTC | ||||||||||||
| TMTV >147 cm3 | 3.5 | 1.6-7.8 | .0016 | 4.4 | 2.0-9.5 | .0002 | 3.9 | 1.2-12.4 | .024 | 5.5 | 1.7-17.9 | .0043 |
| IPET2 | 9.2 | 4.1-20.6 | <.0001 | 10.9 | 4.9-24.4 | <.0001 | 8.8 | 2.7-28.7 | .0003 | 11.1 | 3.4-36.4 | <.0001 |
| U EORTC | 3.2 | 0.9-11.1 | .067 | — | — | .9 | ||||||
| GHSG | ||||||||||||
| TMTV >147 cm3 | 4.1 | 1.8-9.3 | .0006 | 4.4 | 2.0-9.5 | .0002 | 4.8 | 1.4-16.3 | .0115 | 5.5 | 1.7-17.9 | .0043 |
| IPET2 | 10.6 | 4.7-23.9 | <.0001 | 10.9 | 4.9-24.4 | <.0001 | 10.4 | 3.1-34.2 | .0001 | 11.1 | 3.4-36.4 | <.0001 |
| U GHSG | 1.3 | 0.4-4.0 | .69 | 2.0 | 0.2-17.2 | .55 | ||||||
| NCCN | ||||||||||||
| TMTV >147 cm3 | 3.7 | 1.7-8.4 | .00014 | 4.4 | 2.0-9.5 | .0002 | 4.3 | 1.3-14.6 | .0182 | 5.5 | 1.7-17.9 | .0043 |
| IPET2 | 10.2 | 4.5-22.8 | <.0001 | 10.9 | 4.9-24.4 | <.0001 | 10.2 | 3.1-33.4 | .0001 | 11.1 | 3.4-36.4 | <.0001 |
| U NCCN | 1.8 | 0.6-5.7 | .30 | 2.9 | 0.3-25.0 | .34 | ||||||
All variables integrated in the Cox model; final model: with significant factors after performing the backward stepwise Cox model.